Overall survival (%) | 73.9% |
Engraftment source | Â |
 Father | 19 (70.4) |
 Mother | 8 (29.6) |
HLA-matched | Â |
 5/10 (3/6) | 18 (66.7) |
 6/10 | 2 (7.4) |
 7/10 | 4 (14.8) |
 5/6 | 2 (7.4) |
 9/10 | 1 (3.7) |
Conditioning regimen | Â |
 TBI (12) + Cy (120) | 1 |
 Flu (120–150) + Bu (16–19.2) + Cy (200) | 26 |
Blood type | Â |
 Matched | 12 |
 Mismatched | 15 |
Stem cells infused | Â |
 MNC × 108/kg | 23.12 (10.04–51.90) |
 CD34+  × 106/kg | 10.22 (5.96–24.88) |
aGVHD (%) | 21/27 (77.8) |
 Stage I–II | 20 |
 Stage III | 1 |
 Stage IV | 0 |
cGVHD (%) | 11/27 (40.7) |
Infection | Â |
 CMV infection (dead/alive) | 0/15 |
 EBV infection, reactivated | 10 |
 Bacterial | 12 |
Haemorrhagic cystitis | 3 |
HVOD (%) | 5 (18.5) |
Engraftment failure | 0 |